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1. Introduction 
Worldwide, countries continue to face an epidemic of obesity, the number one risk factor for 
diabetes and hypertension. Obesity likely mediates, at least in part, the majority of kidney 
disease among industrialized societies. Due to the rising prevalence of obesity, the incidence 
of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) will likely not 
decrease over the next several decades, but may in fact increase. The impact of obesity is 
especially important for kidney transplantation because many obese individuals are 
precluded from kidney transplantation due to concerns over the potential medical and 
surgical complications associated with their body habitus. Because higher BMI appears to be 
associated with decreased mortality among patients receiving dialysis, clinicians may be 
reluctant to counsel obese patients to lose weight. To understand the impact of obesity on 
transplantation, the discussion needs to begin with a review of how obesity impacts 
mortality in populations with CKD. This chapter will then discuss trends in obesity among 
adults receiving dialysis, controversies surrounding the preclusion of morbidly obese 
individuals from transplantation, and behavior modifications and surgical interventions and 
their respective risks and benefits for obesity management. 
2. BMI and mortality in the general population 
Body mass index (BMI) (the weight in kilograms divided by the square of the height in 
meters) has been widely used to estimate overweight and obesity. Weight indexed for 
height was first used by life insurance companies to estimate life expectancy in the early 
part of the twentieth century (1, 2). In 1997, the World Health Organization (WHO) created 
categories for underweight (BMI<18.5 kg/m2), overweight (BMI 25.0-29.9 kg/m2), and 
obesity stages I (BMI 30.0-34.9 kg/m2) , II (BMI 35.0-39.9 kg/m2), and III (≥40 kg/m2) (Table 
1) (3). Controversy exists as to whether these BMI categories are applicable for assessing 
mortality risk in all age and racial/ethnic groups. However, in the general U.S. population, 
studies have consistently shown that a BMI ≥ 35 kg/m2 heightens mortality risk in young 
and middle-aged individuals (4-6) but this risk declines with advancing age (7). A meta-
analysis of studies limited to adults 65 years or older concluded that federal guidelines for 
ideal weight (BMI 18.7-25 kg/m2) may be too restrictive for populations over the age of 70 
years due to lack of  evidence that overweight in the elderly confers excess mortality risk (8).  
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BMI (kg/m2) 
Underweight <18.5 
Normal 18.5-24.9 
Overweight  25.0-29.9 
Class I Obesity 30.0-34.9 
Class II Obesity  35.0-39.9 
Class III Obesity 40 
Waist circumference (cm) 
Increased risk  
Men  102 
Women  88 
Decreased risk 
Men >102 
Women >88 
*Adapted from World Health Organization 1998 guidelines for obesity classification (3) 
Table I. Classification of Underweight, Overweight, and Obesity by BMI and Waist 
Circumference* 
3. Abdominal obesity in the general population 
The indexing of weight for height (BMI) includes fat mass and fat-free mass and provides no 
information about body composition or regional adiposity. Abdominal fat remains a strong 
predictor of mortality even after adjustment for sensitive measures of total body fat. In fact, 
the increased cardiovascular risk associated with obesity is mainly mediated by abdominal 
fat (9). Visceral adipose tissue produces cytokines including tumor necrosis factor alpha, 
which can cause insulin resistance by the suppression of adiponectin. Abdominal obesity 
can amplify this problem by the high influx of portal fatty acids, cytokines, and hormones 
into the liver from omental adipocytes, resulting in increased hepatic synthesis of 
apolipoprotein B and very low density lipids (10). Although abdominal fat can be measured 
directly by using dual-energy X-ray absorptiometry, computed tomography, or magnetic 
resonance imaging, waist circumference correlates highly with abdominal fat and can be 
measured easily and fairly reliably (11-13). The definition of abdominal adiposity (waist 
circumference ≥102 cm in men and ≥88 cm in women) is based on a Scottish study which 
found that this threshold for waist circumference effectively identified obese (BMI 
≥30kg/m2) individuals in addition to adults with BMI < 30 kg/m2 in the setting of a high 
waist/hip ratio (Table 1) (14). While waist circumference thresholds for abdominal adiposity 
may differ by racial/ethnic groups (i.e. > 87cm and > 83cm in Japanese men and women, 
respectively) (15), individuals with abdominal adiposity are more likely to have 
hypertension, diabetes, dyslipidemia, and the metabolic syndrome than individuals without 
abdominal adiposity,  even after adjusting for BMI class (16, 17). Furthermore, abdominal 
adiposity is associated with increased mortality risk regardless of BMI or racial/ethnic 
group (16-18).  
4. Obesity trends in CKD stages 1-5 
Rates of obesity worldwide have increased dramatically over the past 20 years. In the U.S., 
prevalence of obesity has doubled from 15 to 30% while morbid obesity prevalence 
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increased by four-fold (19). Overall, obesity trends in adults with ESKD mirror those in the 
general population. Not surprisingly, during years 1995-2002, the mean BMI among patients 
initiating dialysis increased from 25.7 to 27.5 kg/m2 (20). The percentage of incident ESKD 
patients who had stage II obesity (BMI>35 kg/m2) during this timeframe increased from 
9.4% to 15.4%. Likewise, the percentage of patients listed for kidney transplantation who 
were obese (BMI≥30kg/m2) increased from 11.6% to 25.1% between the years 1987 and 2001 
(21).  
5. Adiposity measures and mortality in adults with CKD 
Using BMI measures as a proxy of adiposity in CKD patients may not account for 
differences in body composition or muscle wasting. Indeed, studies using BMI to study 
adverse outcomes in the CKD population have shown conflicting results from the general 
population (22-24). Similarly, in studies of adults with CKD who are not receiving dialysis, 
BMI has not been found to be an independent predictor of cardiovascular disease or all-
cause mortality (25,26). To examine associations between abdominal adiposity as measured 
by the waist-hip ratio (WHR) and BMI with cardiovascular events, Elsayed et al pooled data 
from the Atherosclerosis Risk in Communities Study and the Cardiovascular Health (ARIC) 
Study (27). A total of  1,669 adults with CKD were followed for a mean of 9.3 years. Mean 
age was 70.3 years and mean estimated glomerular filtration rate (eGFR) was 51.1 
ml/min/m2. The highest WHR group had a 36% increased hazard of cardiovascular events 
compared to the lowest WHR group. Obesity (BMI>30 kg/m2) was not associated with 
cardiovascular events when compared to those with an ideal BMI (18.5-24.9 kg/m2).  
Among adults receiving dialysis, numerous studies have reported a survival benefit with 
higher BMI compared to BMI in the ideal (18.5-24.9 kg/m2) and low (< 18.5 kg/m2) range 
(28-31). It has been posited that fat may play a protective role in these patients who often 
suffer from protein-energy malnutrition and inflammation (28). However, BMI represents 
both muscle mass and abdominal and peripheral fat. Higher muscle mass reflects better 
physical functioning, which is extremely important for predicting mortality in patients with 
co-morbid conditions such as ESKD. An Italian study of 537 dialysis patients examined 
associations of waist circumference, waist-to-hip ratio (WHR), and BMI with cardiovascular 
and total mortality (32). The inverse relationship between BMI and mortality was reaffirmed 
whereas waist circumference and WHR were directly associated with increased 
cardiovascular and total mortality. After adjustment for cardiovascular risk factors, every 
10-cm higher waist circumference conferred an excess 26% risk for death and an excess 38% 
risk for cardiovascular death (32). The association between BMI and mortality in patients 
receiving dialysis has also been shown to be modified by muscle mass as reflected by 24-
hour creatinine excretion (33). 
Few studies have examined the link between adiposity measures and mortality in adult 
kidney transplant recipients. Kovedsky examined BMI and waist circumference in 993 
kidney transplant recipients in Hungary (34). Mean age was 50.9 years, 21% were diabetic, 
and mean eGFR rate was 50.9 ml/min/1.73 m2. Individuals with higher BMI or waist 
circumference were more likely to be diabetic, less likely to smoke, and more likely to have 
had delayed graft function. While risk of mortality declined with higher BMI, a 15 cm higher 
waist circumference was associated with greater than 2-fold increase in all-cause mortality 
after adjustment for BMI (34).  
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In summary, BMI may be inadequate by itself to assess mortality risk associated with 
adiposity. Waist circumference reflects visceral adiposity burden and is directly associated 
with mortality among individuals with co-morbid conditions such as ESKD while BMI 
appears to be inversely related to mortality (30-32, 34). Many centers currently exclude 
patients with BMI >35 kg/m2 from kidney transplantation until they are able to lose weight 
(35, 36). Use of waist circumference in the evaluation of kidney transplant candidates may 
provide more accurate information regarding the pre- and post-transplantation risks 
associated with obesity.  
6. Access to kidney transplantation and barriers due to obesity 
Obesity is currently an important barrier keeping many individuals from being listed for 
kidney transplantation (37). A study of the UNOS database from 1995-2006 evaluated the 
association between BMI and time to transplantation (38). Individuals with severe obesity 
(BMI 35-40 kg/m2) and morbid obesity (BMI 40-60 kg/m2) at time of initial listing were 28% 
and 44% less likely, respectively, to receive a deceased-donor kidney transplant compared to 
individuals with an ideal BMI (18.5-24.9 kg/m2) (38). This study could not account for the 
number of obese individuals who were never listed at all due to their weight, and likely 
underestimates the impact obesity may have on access to transplantation. Indeed, 15% of 
transplant centers did not list a single severely obese (BMI 35-40 kg/m2) patient during the 
11-year period of the study (38). While this study cannot prove causality, it seems likely that 
body habitus is a major deciding factor when determining whether a person may be listed 
for transplantation. Certainly, economic pressures favor kidney transplantation for “low-
risk” non-obese patients in which complication rates and hospital stay may be lower. 
Moreover, obesity is considered a reversible risk factor, and losing weight prior to 
transplant is thought to be beneficial, especially considering how common weight gain is 
after kidney transplantation (37). Obese kidney transplant recipients are at increased risk for 
short-term complications including delayed wound healing, longer surgical times, and 
delayed graft function (39, 40). Data on whether obese transplant recipients are at higher 
risk for long-term adverse outcomes remains controversial, but the majority of larger studies 
suggest poorer long-term outcomes among obese individuals compared to non-obese 
individuals (40-42). 
The decision by some transplant centers to use BMI thresholds for the exclusion of patients 
from kidney transplantation should consider both societal and individual level concerns. 
From an individual-level perspective, kidney transplantation offers a clear survival benefit 
over dialysis regardless of obesity status (43,44). Among obese adults receiving dialysis for 
ESKD during years 1995-1999,  both living and deceased donor kidney transplant recipients 
had decreased mortality risk of 61% and 77%, respectively, compared to those remaining on 
the kidney transplant waiting list. Due to the excess surgical risks and graft failure among 
obese individuals, one option would be to limit opportunities for cadaveric kidneys. 
However, evidence for this is contentious. Excluding obese individuals due to increased risk 
ignores the fact that co-morbid conditions such as diabetes pose similar risk as obesity yet 
these conditions do not preclude transplantation (40). Transplantation centers should also 
consider the extra time an obese patient spends on dialysis while trying to lose weight in 
order to be listed for transplantation. Unfortunately, weight loss is usually unsuccessful for 
individuals with severe obesity (45).  
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7. Obese kidney transplant patients 
7.1 Post-operative complications 
For all surgical procedures, obesity can complicate the post-operative period with delayed 
wound healing, increased rates of ventral hernias, and longer operating times and 
hospitalizations. In transplant recipients, obesity is also associated with heightened risk of 
infections,  and post-transplant diabetes (49-53). One single-center study which included 
2013 adult kidney transplants performed between 1984 and 1998, superficial or deep wound 
infections occurred in 4.8%, whereas 3.6% developed either a fascial dehiscence or hernia of 
the wound (54). Those with BMI ≥ 30 kg/m2 had a 340% increased risk for a wound 
infection and 182% increased risk for a fascial dehiscence or incisional hernia compared to 
those with BMI < 30 kg/m2.  
Delayed graft function (DGF), defined as the need for dialysis therapy in the first week after 
kidney transplantation, places a recipient at increased risk for chronic rejection and 
decreased graft survival. Only a minority of single-center studies have shown that obesity 
increases risk for decreased graft survival after kidney transplantation (46-53) but this may 
be due to small sample sizes in these single-center studies. In a large study which included 
51,927 kidney transplant recipients,  severe obesity (BMI > 35 kg/m2) was associated with a  
51% increased risk of DGF compared to the transplant recipients with a BMI between 22-24 
kg/m2 (41). These findings were supported by a study which included data from 27,377 
kidney transplant recipients (40).  
Overall mortality, regardless of obesity status, is substantially reduced with kidney 
transplantation (43,44). However, compared to non-obese kidney transplant recipients, 
obese transplant recipients appear to have an increased risk of graft loss although not all 
studies agree (39-56). Overall, BMI > 35 kg/m2 appears to increase graft failure risk by 
approximately 20-30% compared to recipients who are not obese while no excess risk is seen 
among transplant recipients with a BMI between 30-35 kg/m2 (40,41). The magnitude of the 
association between morbid obesity and graft failure is similar to the increased risk of graft 
failure associated with diabetes (40). Overall mortality after kidney transplantation does not 
appear to be associated with obesity itself. However, obese patients may have co-morbid 
conditions which influence survival (40).  
7.2 Weight loss interventions for obese adults with CKD 
7.2.1 Who should lose weight 
The management of obesity requires identification of individuals who will benefit from 
weight loss. All obese patients (BMI ≥ 30 kg/m2) should be counseled to modify their 
lifestyles (diet and physical activity) to induce weight loss but goals must be individualized 
(57). In adults with CKD, abdominal obesity, measured by waist circumference should be 
considered an indication for weight loss considering the increased risk of cardiovascular 
and total mortality associated with increased waist circumference (27, 32, 34). Weight loss in 
patients with diabetic and non-diabetic kidney diseases has been shown to reduce 
proteinuria (58, 59). However, there is a paucity of data regarding the long-term outcomes of 
intentional weight loss in adults with CKD. Perhaps the strongest evidence supporting 
weight loss in this population comes from surgical intervention studies in the morbidly 
obese. Successful weight loss dramatically improves blood pressure, proteinuria, and in 
some cases, stabilizes GFR (60-63). However, surgical interventions for obesity carry 
significant risks as discussed later.  
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Regardless of the small survival benefits associated with obesity observed among patients 
receiving dialysis, kidney transplantation greatly improves longevity and survival is 
substantially higher among obese kidney transplant recipients compared to individuals 
remaining on the waiting list (38). In fact, obesity should be considered the most important 
modifiable mortality risk factor if a patient receiving dialysis is not listed for kidney 
transplantation solely due to obesity (45). Weight loss goals for obese patients receiving 
dialysis who are seeking kidney transplantation must be assessed individually and goals 
should account for the obesity-related co-morbid conditions and nutritional status of that 
individual. Moreover, interventions should also account for the patient’s body composition 
because increasing muscle mass may improve overall fitness and survival (31, 45).  
7.2.2 Weight gain after kidney transplantation 
Weight gain after kidney transplantation is very common, with studies showing increased 
weight between 8-14 kg one year post-transplant (37, 39, 64). Johnson et al showed that a 
10% weight gain correlated with increased serum cholesterol and triglyceride levels which 
may heighten cardiovascular risk (49, 65). In a study of 3,899 white Australian and New 
Zealand adults, weight gain of 10% to 19.9% during the first year after transplantation and 
stable weight (0% to 4.9% gain) during the second year after transplantation were associated 
with the best outcomes while weight loss over the first two years after transplantation was 
associated with the worst outcomes (66). A 20% weight gain above the pre-transplant 
weight during the first year with continued weight gain during the second year after 
transplantation was associated with increased graft loss and mortality compared to 
transplant recipients who maintained their weight after the second year.  
Certain individuals may be at higher risk for excessive weight gain after kidney 
transplantation than others. Certainly the improved appetite and sense of well-being may 
lead to augmented caloric intake. A study of renal transplant recipients from a racially 
diverse center between 1983 and 1998 reported that African Americans were at higher risk 
for weight gain (67), and these results have been supported by several other studies (47, 49, 
50, 64). Part of this race disparity may be due to socioeconomic status because accounting 
for income level attenuates the association between race and weight gain after kidney 
transplantation (64). Weight gain patterns after transplantation seem to mirror the general 
population as the majority of studies have shown that younger age, female sex and low 
income-status increase the probability of weight gain (47, 49, 50, 64). Patients who are obese 
at the time of kidney transplantation appear to have similar (67) or greater weight gain (47, 
64) compared to non-obese kidney transplant recipients.  
Immunosuppressant medications have varying adverse cardiovascular risk profiles. 
Corticosteroids can cause excessive weight gain and redistribution of fat to undesired areas 
(face and back) as well as worsen blood pressure, glucose and lipid metabolism (68). 
Overall, steroid doses used for kidney transplantation are much lower than in the past with 
some transplant protocols minimizing or avoiding steroid use. However, minimization or 
avoidance of steroid use in kidney transplantation must be counterbalanced with adequate 
immunosuppression, which often requires lymphocyte depleting agents or anti-IL2 
strategies coupled with the use of other immunosuppressive medications (69). One study 
examined 95 kidney transplant recipients enrolled in National Institutes of Health clinical 
transplant trials (70). Regardless of therapy received,  weight increased by 5 kg (not BMI) on 
average among all patients at one year post-transplant. Another small retrospective study 
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compared patterns of weight gain among 301 kidney transplant recipients receiving chronic 
corticosteroid therapy to patients who had early corticosteroid withdrawal (within 7 days 
post-transplant) (71). A 33% lower rate of weight gain among the early corticosteroid 
withdrawal group was observed. In contrast, a Dutch study which included 123 patients 
found no difference in one year post-transplant weight gain between patients who were and 
were not maintained on low dose steroids (72). In a study of 334 transplant patients at a 
single institution, average weight gain in patients treated with a steroid taper to 10 mg/day 
over the course of a year was 28.5% lower compared to the group in whom the steroid dose 
was tapered to 5mg/day at 6 months (73). The benefits of corticosteroid-sparing regimens 
on weight gain as well as long-term outcomes are yet uncertain and deserve further study.  
7.3 Weight management before and after kidney transplantation 
7.3.1 Lifestyle modifications 
A multidisciplinary approach to weight management is necessary to maximize weight loss. 
This approach should utilize all members of the kidney transplant or CKD team including 
dieticians, nurses, psychologists, social workers and physicians. These members should 
work together to identify specific needs, motivations, and barriers for each individual 
patient who requires weight loss. For most patients, a combined approach including diet, 
exercise and behavior modifications, similar to methods used in the general population, 
should be applied. Preclusion of kidney transplantation due to obesity generally focuses on 
BMI thresholds > 35 kg/m2. Patients with this level of obesity will frequently fail traditional 
methods for weight loss and surgical interventions should be considered after a trial of 
lifestyle changes. In the following paragraphs, we describe traditional dietary changes for 
weight loss and the benefits of exercise in patients with CKD. This is then followed by a 
discussion of the risks and benefits of weight loss drugs and bariatric surgery.  
7.3.2 Dietary interventions for patients not receiving dialysis 
Dietary modification remains the most important component of any weight loss 
intervention and dietary interventions have been shown to be effective in ameliorating 
weight gain after kidney transplantation (74-76). As weight gain is quite common after 
kidney transplantation, dietary counseling prior to kidney transplantation with frequent 
follow-up after transplantation should be done. To aid in developing a plan, a diet history 
should be obtained and patients can take part in this plan by keeping a food diary for 
several days. Review of medications that may contribute to weight gain should be 
completed. While numerous diets exist, none can be universally recommended for patients 
with CKD including the kidney transplant recipient (77). A conservative approach is to 
restrict caloric intake by approximately 500 kcal/day, which in the absence of physical 
activity changes, will lead to a weight loss of 1 pound per week (74). More restrictive diets 
(<1,200 kcal/day) require more intensive monitoring of the nutritional status and well-being 
of the patient.  
With the exception of protein intake, there are no exact recommendations for specific 
nutrient and dietary composition for patients with CKD. The American Heart Association 
guidelines for a healthy lifestyle provide no specific recommendations for diet and state that 
the exact percentage of carbohydrates, proteins, and fat within a given meal will not in itself 
influence weight management (78). Addressing portion size and reducing energy intake to 
less than energy expenditure is the only reliable way to facilitate weight loss (78). High 
protein diets for weight loss are quite popular and can be successful for some individuals, 
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but data on long-term safety is lacking (79). High protein diets should be avoided in adults 
with CKD due to concerns that higher protein intake can accelerate loss of GFR (80). 
Accordingly, the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative 
(NKF-KDOQI) guidelines recommend that protein intake not exceed 0.8g/kg/day with 50 
to 75% of the protein derived from lean poultry, fish, and vegetables (81). This level of 
protein intake is substantially lower than the average protein intake in many individuals in 
the U.S. and other countries where protein intake may exceed 1.2 gm/kg/day. Diets such as 
the Dietary Approaches to Stop Hypertension (DASH) diet emphasize the consumption of 
fresh fruits and vegetables, whole grains, and low dairy while minimizing red meat intake, 
sodium intake and processed foods. The DASH diet may provide additional benefits 
beyond those associated with weight loss (82). However, the DASH diet contains higher 
levels of protein (1.4 g/kg/d), potassium (4500mg/d), and phosphorus (1.7g/d) than 
recommended by the NKF-KDOQI guidelines for the CKD patient (74). Specific nutritional 
recommendations for CKD and kidney transplant recipients remain poorly defined, and 
more research needs to be done to better define an optimal diet before making specific 
recommendations. Thus, diet interventions for the CKD patient must be individualized and 
focus should be on portion size reduction. Identification of excess snacking times (e.g. night 
time) and intake of nutrient poor yet high calorie foods will help the individual patient 
reduce their caloric intake. In general, the weight loss goals should not exceed 1 pound per 
week. 
7.3.3 Dietary interventions for patients receiving dialysis 
Studies to support dietary recommendations for patients receiving dialysis to promote 
weight loss are substantially limited. Current guidelines for patients receiving dialysis 
recommend protein intake of 1.2g/kg/day and 30 to 35 kcal/kg/day for stable patients (81). 
However, in order to lose weight, obese patients must reduce caloric consumption to less 
than caloric expenditure. Nutritional plans should be individualized to ensure that the 
unique nutritional requirements of patients receiving dialysis are met. Food diaries and 
dietary histories can be used to help identify sources of empty calories. There is no strong 
evidence to suggest any particular dietary intervention to promote weight loss in patients 
receiving dialysis. One conservative approach is to start with 25 kcal/kg/d based on the 
adjusted body weight (ideal body weight – [dry total body weight – ideal body weight]/4) 
and then adjustments can be made based on the patient’s weight loss (45). However, this 
method is not as reliable as using direct measures of resting energy expenditure to 
determine caloric needs. Additional research is needed to determine safe and effective 
interventions for weight loss in this patient population.  
7.3.4 Dietary interventions for kidney transplant recipients 
Several studies have examined dietary interventions to ameliorate weight gain after kidney 
transplantation. One single-center study gave 11 consecutive kidney transplant recipients 
individualized, intensive dietary advice for the first 4 months after transplantation (76). These 
individuals were then compared to 22 patients who received kidney transplants 4 years prior 
to the study and had not received dietary advice post-transplantation. Baseline characteristics 
of the two groups were similar with mean BMI of about 24 kg/m2 in both groups. The group 
who received dietary advice showed no statistically significant change in weigh four months 
after transplantation compared to their pre-transplant weight. In contrast, the group with no 
dietary intervention had a significant weight gain of 7kg four months after transplantation and 
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11.8 kg at one year after transplantation (76). Another study enrolled 34 overweight and obese 
(mean BMI 33 kg/m2) kidney transplant recipients who were highly motivated to lose weight 
in a weight loss program (83). During the initial visit, the negative impact of obesity after 
kidney transplantation was discussed and participants wrote down and reviewed a detailed 3-
day history of their own dietary habits but no dietary advice was given. After six months of 
follow-up, only 27% of those in the weight loss program had weight gain compared to 80% of 
controls (83). While these two studies were not randomized controlled clinical trials, the study 
results support a beneficial role for dietary counseling after kidney transplantation. Transplant 
centers should utilize an approach whereby all potential kidney transplant recipients receive 
some individualized counseling on lifestyle (diet and physical activity) both before and after 
kidney transplantation. The use of dietary histories and food diaries are encouraged because it 
will enable the patient to participate in the development of plans to facilitate changing their 
own dietary habits.  
8. Exercise 
Increasing physical activity may promote modest weight loss and improve physical 
functioning. Patients with CKD are overall a sedentary population with markedly reduced 
peak maximal oxygen and reduced physical functioning compared to individuals with 
normal kidney function (84, 85). A study of ambulatory patients new to dialysis found that 
physical activity scores for these patients were below the 5th percentile of healthy 
individuals and estimated that 95% of patients initiating dialysis have very low fitness levels 
(84). Decreased physical activity is associated with excess mortality in adults with CKD (85, 
86). Exercise in patients with CKD improves functional aerobic capacity, muscular strength, 
and blood pressure (87, 88). However, currently there is insufficient evidence to make 
specific exercise recommendations for patients with CKD. In addition, the co-existence of 
multiple co-morbid conditions in this patient population limits the capacity to exercise. In 
any case, considering the poor physical functioning demonstrated in the majority of patients 
receiving dialysis, exercise should be encouraged if possible (84). Low-to-moderate-intensity 
aerobic exercise three times per week should be recommended to all patients able to do so, 
just as it is recommended for the general population (89). The risk of cardiac events during 
exercise has not been quantified in patients with CKD,  but the risks are likely no greater 
than those occurring during diagnostic tests for cardiovascular disease (3.6 myocardial 
infarctions per 10,000 tests) (90, 91).  
9. Pharmacologic agents for weight loss 
Dietary change remains difficult for the majority of individuals and some patients may 
request weight loss medications to augment weight loss. It should be noted that weight loss 
medications will only modestly improve weight loss and these drugs are frequently 
accompanied by substantial side effects. These possible risks and benefits must be discussed 
with the patient when considering the use of weight loss medications. Moreover, the safety 
of any weight loss drug should be strongly scrutinized given that two weight loss 
medications, sibutramine and rimonabant, were removed from the U.S. and European 
markets due to concerns about heightened risk of cardiovascular disease and suicide, 
respectively (92, 93). This illustrates the need for extreme caution with any weight loss 
medication.   
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In the U.S., the only medication currently approved by the FDA for long-term use is orlistat, 
which can promote modest weight loss but is accompanied by frequent gastrointestinal side 
effects. Short-term agents that are FDA-approved such as phentermine or diethylpropion 
should be avoided in kidney transplant recipients or individuals with CKD due to 
associated conditions such as hypertension, and cardiovascular disease risk. Thus, the only 
weight loss medication that potentially could be safe in populations with CKD is orlistat. 
Orlistat reversibly inhibits gastric and pancreatic lipases and blocks approximately 30% of 
gastrointestinal absorption of triglycerides. Only a small amount of orlistat is systemically 
absorbed with 800 mg of orlistat daily yielding minimal plasma concentrations of the drug 
(94). A small non-randomized trial of orlistat was conducted among patients with stages 3-5 
CKD (95). These participants followed a low-fat renal-specific diet, and exercise was 
encouraged (95). Orlistat was given at the standard dose of 120 mg three times daily and 
patients were followed for two years. An average of 8.3 kg weight loss was noted and this 
loss occurred mostly during the initial six month period of the study. However, the weight 
loss was maintained after two years of follow-up. Gastrointestinal adverse events were 
common including flatulence, diarrhea, and fatty stools, with 43% reporting at least one side 
effect in the initial month of therapy. After six months of orlistat use, only 10% reported side 
effects (95). Thus, orlistat augments weight loss, but only modestly.  
Among kidney transplant recipients, orlistat use may complicate the immunosuppressant 
regimen. Orlistat interferes with cyclosporine absorption because cyclosporine is highly 
lipid-soluble. To prevent this issue, orlistat should not be taken within a two-hour window 
of taking cyclosporine and cyclosporine levels should be closely monitored (96, 97). Another 
concern is the increased risk of oxalate nephropathy with this drug. Although rare, acute 
kidney injury due to renal oxalosis has been reported in an adult with CKD taking orlistat 
for weight loss (98). Patients should also be advised that fat intake must be limited to less 
than 30% of total calories otherwise the patient may experience fecal incontinence. Fat-
soluble vitamin deficiencies can also occur with use of orlistat and it is recommended that 
patients be supplemented with fat-soluble vitamins when taking orlistat (99). 
Other pharmacologic agents such as serotonin reuptake inhibitors and buproprion are not 
approved for long-term use of weight maintenance in the general population, and have not 
been well-studied in adults with CKD. Over-the-counter dietary supplements should also be 
discouraged due to a dearth of evidence regarding efficacy, safety, and possible interactions 
with immunosuppressive medications. 
10. Surgical options 
Surgical options for weight management should only be considered after lifestyle 
interventions fail to yield adequate weight loss. These surgical options include procedures 
that divert food from the stomach into lower parts of the gastrointestinal tract to limit food 
absorption and reduce the size of the stomach leading to early satiety (Roux-en-Y diversion) 
and gastric banding (100). An adjustable gastric band placed around the upper part of the 
stomach may be inflated or deflated by injecting or removing saline through a port 
underneath the skin (100). Given the procedure is performed by an experienced surgeon, 
mortality risk is < 2% with gastric banding and approximately 3% with gastric diversion 
procedures. However, mortality risk may be higher in patients with a BMI≥ 50 kg/m2 (101, 
102). Regardless of the type of procedure, the majority of weight loss occurs during the first 
year after surgery with greater weight loss consistently occurring with gastric diversion 
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procedures (70.1%) vs. gastric banding (47.5%) (101, 102). Advantages of gastric banding 
include less hospitalization time and fewer short-term complications (see Table 2) (103). 
However, long-term complications of gastric banding are higher than gastric diversion 
procedures albeit less severe. For instance, intragastric band erosion is caused by chronic 
ischemia of the gastric wall due to the constrictive effects of the band. The gastric band can 
also migrate and lead to severe abdominal pain and vomiting. A recent report of long-term 
followup at a center in Belgium reported that approximately 1 out of every 3 patients who 
underwent gastric banding experienced gastric band erosion with almost half required band 
removal (104).  
 
 Roux-en-Y Gastric Bypass 
Laparoscopic Adjustable 
Gastric Banding 
Mortality <1% <1% 
Resolution of type 2 
diabetes 
++ + 
Maintenance of weight loss 
after 2 years 
+++ + 
Length of hospitalization 2-8 days 1-3 days  
Short-term complications More common Less common 
Long-term complications 
Less common, but more 
serious (i.e. bowel 
obstruction, marginal ulcer, 
incisional hernia, nutrient 
deficiency) 
More common, but less 
serious (i.e. band slippage 
with pouch dilation, band 
erosion, port problems) 
Reoperation rates§ 10-20% 20-60% 
Vitamin deficiencies 
(B vitamins, fat soluble 
vitamins) 
++ (may require substantial 
supplementation) 
+ (often corrected with 
multivitamin supplement) 
*Adapted from Tice et al. (102) 
§Reoperation rates from studies with long-term follow-up >24 months (102, 121-123)  
Table 2. Comparison of Roux-en-Y Gastric Bypass and Laparoscopic Adjustable Gastric 
Banding* 
Patients receiving dialysis may obtain substantial weight loss allowing for kidney 
transplantation (105-107), but information on risk and long-term benefits remains limited. 
Using Medicare claims data during years 1991-2004 linked with the United States Renal 
Data System, investigators evaluated post-bariatric surgery mortality risk and outcomes 
(108). On average, patients lost 30-60% of their total pre-surgery body weight. Overall 30-
day mortality risk was similar for patients listed for a kidney transplant and for kidney 
transplant recipients (3.5%). Allograft failure was reported in a patient 30 days after the 
kidney transplant (108). The largest single-center series of kidney transplant patients 
reported outcomes for 10 kidney transplant recipients who underwent gastric bypass 
surgery for excessive weight gain leading to morbid obesity after transplantation (109). 
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Mean age was 44 years and the gastric bypass surgeries occurred on average 5.3 years after 
transplantation. In this group, there were no fatalities within the first 30 days after bariatric 
surgery and patients on average lost 70.5% of their excess weight above ideal weight (109).  
Clearly, the substantial weight loss after bariatric surgery can lead to resolution of diabetes 
and less need for blood pressure lowering medications in adults without CKD. In fact, 98% 
and 48% of adults with obesity and diabetes no longer have type 2 diabetes two years after 
undergoing gastric diversion and gastric banding, respectively, for obesity management 
(102). Other obesity related co-morbid conditions may resolve as well such as fatty liver, 
hypercholesterolemia and sleep apnea (101). These long-term benefits likely apply to 
patients with CKD, but the surgical risks may be heightened in this population. Gastric band 
erosion has been reported in a kidney transplant recipient treated with gastric banding for 
weight management (110). While these surgical complications are not unique to the 
transplant population, the presence of immunosuppressant agents could worsen the side 
effects of bariatric surgery.  
Nutritional deficiencies are common after bariatric surgery for weight loss and this may be 
complicated by poor nutritional choices of the individual patient. Patients may become 
deficient in iron, calcium, B vitamins and fat soluble vitamins (101). An important 
complication of gastric bypass surgery includes increased oxalate absorption due to 
decreased intestinal absorption of fatty acids, and this could lead to kidney stones, renal 
oxalosis, acute kidney injury, allograft loss and even oxalate-induced anemia (111-115). The 
Roux-en-Y surgery results in a smaller gastric pouch which may not produce as much acid, 
and as a result, the higher stomach pH and the smaller surface area of both stomach and 
small intestine may impact the absorption of some drugs (116, 117). It should be noted that 
increased cyclosporine dosing may be required after gastric diversion procedures (117). The 
pharmacokinetics of tacrolimus, mycophenolate, and sirolimus may also change after gastric 
diversion, and higher doses of several immunosuppressants may be needed after gastric 
bypass (116). Obese patients often require lower doses of cyclosporine per body weight 
compared to lean recipients (118, 119) and dosing for cyclosporine based on ideal body 
weight is recommended (118-120). Given the excessive weight loss which occurs rapidly 
after bariatric surgery, levels of immunosuppressant drugs including mycophenolate 
mofetil, should be followed closely after gastric bypass surgery, especially during the first 18 
months after bariatric surgery.  
Due to the lack of information on long-term consequences of bariatric surgery, no specific 
recommendations can be made for patients with CKD or kidney transplant recipients. Thus, 
the decision to utilize bariatric surgery for weight management needs to be individualized. 
Most importantly, clinicians must ensure that these patients are informed of the associated 
risks before they proceed with surgical interventions for obesity management.  
Regardless of obesity status, kidney transplantation is associated with improved survival 
and decreased morbidity compared to dialysis. Thus, obesity may be viewed as the most 
important modifiable mortality risk factor for patients precluded from kidney 
transplantation due to obesity status. Weight management should include a multi-
disciplinary approach with dietary advice on caloric restriction and encouragement to 
increase physical activity. Patients should actively take part in the development of the 
obesity management plan (e.g. keep food diary). If lifestyle interventions fail to yield 
adequate weight loss, then surgical options should be considered. Clinicians should discuss 
frankly the potential risk of bariatric surgery for weight management. Transplant centers 
should also incorporate dietary counseling both before and after kidney transplantation to 
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ameliorate weight gain after transplantation which may heighten cardiovascular risk. Future 
research should address the use of both BMI and waist circumference to improve risk 
stratification and obesity interventions for patients before and after kidney transplantation. 
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